EXETER, N.H., Feb. 29, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX: VAPO), ('Vapotherm' or the 'Company'), a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity therapy® products for patients of all ages experiencing respiratory distress, is pleased to announce the regulatory approval of the HVT 2.0 system in Brazil..

新罕布什尔州埃克塞特，2024年2月29日/PRNewswire/--Vapotherm，Inc.（OTCQX:VAPO），（“Vapotherm”或“公司”）是一家全球医疗技术公司，专门为患有呼吸窘迫的所有年龄段的患者开发和商业化其专有的Vapotherm high velocity therapy®产品，很高兴地宣布巴西HVT 2.0系统的监管批准。。

The therapeutic respiratory devices market in Brazil, valued at USD 302.4 million in 2022, is anticipated to grow at a CAGR of 6.5% from 2023 to 2030.1 With approximately 8 million cases of COPD and a growing aging population, there is an increasing demand for respiratory devices in the country. COPD stands as a significant health concern in Brazil, ranking sixth leading cause of death.2.

2022年，巴西的治疗性呼吸设备市场价值为3.024亿美元，预计2023年至2030年的复合年增长率为6.5%。1随着大约800万COPD病例和人口老龄化的增加，该国对呼吸设备的需求不断增加。COPD在巴西是一个重要的健康问题，居第六大死因。

Joe Army, Vapotherm's President and Chief Executive Officer expressed his optimism, stating, 'I'm excited about emerging market growth for Vapotherm. In the third quarter of 2023, we posted 25% global capital equipment revenue growth compared to the third quarter of 2022, partly driven by sales in Brazil.

Vapotherm总裁兼首席执行官乔·阿马尔（JoeArmy）表示乐观，他说：“我对Vapotherm新兴市场的增长感到兴奋。2023年第三季度，与2022年第三季度相比，我们的全球资本设备收入增长了25%，部分原因是巴西的销售额。

With the approval and subsequent launch of HVT 2.0 in Brazil, we look forward to establishing ourselves as a frontline solution in Latin America.'.

随着HVT 2.0在巴西的批准和随后的推出，我们期待着成为拉丁美洲的一线解决方案。”。

The mobility of the HVT 2.0 platform, ease of use, multi-functionality, and the upgraded design which freed the device from requiring an external source of compressed air makes HVT 2.0 an ideal respiratory support device for care of patients ranging from pediatric to the elderly. These features facilitate optimal patient care in the most advanced hospitals as well as resource constrained environments..

HVT 2.0平台的移动性、易用性、多功能性以及升级设计使该设备不再需要外部压缩空气源，使HVT 2.0成为从儿科到老年患者护理的理想呼吸支持设备。这些功能有助于在最先进的医院以及资源受限的环境中实现最佳的患者护理。。

With the approval of the new system in Brazil, Vapotherm is launching a new Portuguese website and social media campaign. The Company attended in the XXVIII Brazilian Congress of Intensive Care Medicine, the largest event of its kind in Latin America, to collaborate with approximately three thousand clinicians..

随着巴西新系统的批准，Vapotherm正在启动一个新的葡萄牙网站和社交媒体活动。该公司参加了第二十八届巴西重症监护医学大会，这是拉丁美洲同类活动中规模最大的一次，与大约3000名临床医生合作。。

About Vapotherm

关于Vapotherm

Vapotherm, Inc. (OTCQX: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders.

Vapotherm，Inc.（OTCQX:VAPO）是一家上市的先进呼吸技术开发商和制造商，总部位于美国新罕布什尔州埃克塞特。该公司开发了创新，舒适，无创的技术，用于慢性或急性呼吸障碍患者的呼吸支持。

Over 4.2 million patients have been treated with the use of Vapotherm high velocity therapy® systems. For more information, visit www.vapotherm.com..

使用Vapotherm high velocity therapy®系统治疗了420多万名患者。有关更多信息，请访问www.vapotherm.com。。

Vapotherm high velocity therapy is mask-free non-invasive respiratory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The HVT 2.0 and Precision Flow systems' mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies.

Vapotherm高速治疗是无面罩的无创呼吸支持，是缓解呼吸窘迫（包括高碳酸血症，低氧血症和呼吸困难）的一线工具。它可以用一种工具快速，安全地治疗未分化的呼吸窘迫。HVT 2.0和Precision Flow systems的无面罩界面可提供最佳调节的呼吸气体，使患者感到舒适，并降低与面罩疗法相关的风险和护理复杂性。

While being treated, patients can talk, eat, drink and take oral medication..

在接受治疗时，患者可以说话、吃饭、喝水和口服药物。。

Legal Notice Regarding Forward-Looking Statements

关于前瞻性声明的法律通知

This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995, including statements about the Company's business and growth prospects in Brazil. In some cases, you can identify forward-looking statements by terms such as 'expect,' 'anticipate,' 'continue,' 'plan,' 'intend,' 'will,' or 'typically,' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words, and the use of future dates.

本新闻稿包含1995年《私人证券诉讼改革法案》下的前瞻性声明，包括有关该公司在巴西的业务和增长前景的声明。在某些情况下，您可以通过诸如“预期”、“预期”、“继续”、“计划”、“打算”、“意志”或“通常”等术语或这些术语的否定词或其他类似表达来识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些词语，并且使用了未来日期。

Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the failure of the Company's products to achieve market acceptance or significant market growth in Brazil and the other risks and uncertainties included under the heading 'Risk Factors' in Vapotherm's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on February 22, 2024, and in its subsequent filings with the SEC.

每个前瞻性声明都存在风险和不确定性，这些风险和不确定性可能导致实际结果与该声明中明示或暗示的结果存在重大差异。适用的风险和不确定性包括公司产品未能在巴西获得市场认可或市场大幅增长，以及Vapotherm于2024年2月22日向SEC提交的截至2023年12月31日的10-K表年度报告中“风险因素”标题下的其他风险和不确定性，并在随后提交给SEC的文件中。

The forward-looking statements contained in this press release reflect Vapotherm's views as of the date hereof, and Vapotherm does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law..

本新闻稿中包含的前瞻性声明反映了Vapotherm截至本新闻稿发布之日的观点，Vapotherm不承担也明确否认任何义务更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。。

Investor Relations Contacts:John Landry, SVP & CFO, ir@vtherm.com, +1 (603) 658-0011

投资者关系联系人：John Landry，高级副总裁兼首席财务官，ir@vtherm.com，+1（603）658-0011

http://investors.vapotherm.com/

http://investors.vapotherm.com/

1 https://www.grandviewresearch.com/industry-analysis/brazil-therapeutic-respiratory-devices-market-report2 https://pubmed.ncbi.nlm.nih.gov/17416152/

1个https://www.grandviewresearch.com/industry-analysis/brazil-therapeutic-respiratory-devices-market-report2（笑声）https://pubmed.ncbi.nlm.nih.gov/17416152/

SOURCE Vapotherm, Inc.

来源：Vapotherm公司。